Mr. Byrnes has over 20 years of experience in the biotechnology industry both in private and public companies; spanning all phases of development from pre-clinical to pre-commercial and across multiple indications including oncology. Prior to joining Fore, Mr. Byrnes was the chief financial officer for eFFECTOR Therapeutics, where he took the company public in 2021. Previous to that, Mr. Byrnes was senior vice president of finance at Principia Biopharma, Inc. (PRNB), which was acquired by Sanofi in September 2020. Prior to that, Mr. Byrnes served as chief financial officer of Alkahest, Inc. from May 2018 to January 2020 and chief financial officer of Ocera Therapeutics, Inc. (OCRX), from December 2014 until its acquisition by Mallinckrodt Pharmaceuticals in 2017.
Earlier in his career, Mr. Byrnes held finance positions of increasing responsibility from 2000 to 2014 with Maxygen, Inc. (MAXY), NeurogesX, Inc. (NGSX), Lipid Sciences, Inc. (LIPD) and ADAC Laboratories, Inc. (ADAC). Mr. Byrnes is a member of the board of directors and audit committee chair of CERo Therapeutics Holdings, Inc. (CERO). Mr. Byrnes received his B.S.C in finance from Santa Clara University and an M.B.A. from California State University, Hayward.
